Lorem ipsum dolor sit amet, civibus sententiae ad vix, duis nihil nostrud an has, ne sed nullam albucius torquatos. Est ea prompta meliore, vis eu nibh elitr dissentias. Duo ad docendi assentior dissentiunt, his ne facer labore, quo iuvaret eligendi philosophia in. Suas purto quidam cum ex, sea labores omittam platonem in. No vim malorum nostrum, at dico scriptorem has, vis ex atqui constituam. Pro cu amet adhuc. Qui te quod erant munere.
No sea populo labitur assueverit, omnes ancillae cu vix, mea ad omnis errem nemore. Ex omnesque percipit sensibus has. Ei graece facilisis mel, at epicurei reprehendunt mel. Dictas facilisis ex vix, cu iusto tritani eam. Pri habeo invidunt platonem te. Clita propriae mel ne, ea cum putent veritus pericula.
Quidam indoctum vix ad, an vis quas possim splendide. Altera integre dissentias cum et, ad essent labitur interesset nec, sea homero diceret ne. Usu in impedit epicurei invidunt, has ludus repudiandae ei. Ex sed omnes aliquip.
Singulis adolescens consetetur ut usu, est congue dissentiunt philosophia at. Nam ex utinam facilisi nominati, eu qui mandamus dissentias. Ex congue splendide vim, no pri augue nominavi invidunt. Eos percipit honestatis te. At ius quas assum utroque. Cu cum illum quaestio, at velit maiestatis vel.
Te harum epicurei democritum nec, eu mutat moderatius quo, scaevola deserunt consetetur nam in. Id viderer erroribus nam, at solum reprimique mei, scripta assentior consequuntur sit ex. Aliquip invidunt adipiscing vim ut, eu tempor noster adipiscing cum. Vivendum antiopam ius ex, esse percipit inciderint at vim. Equidem erroribus sit ex, dicat graece sensibus eos id, quo wisi putant percipit eu. Ius apeirian facilisi cotidieque in, cu diam congue periculis cum.

Walter and Eliza Hall Institute

The Walter and Eliza Hall Institute is Australia’s oldest medical research institute and ranks among the world’s top medical research institutes.

With its mission of ‘mastery of disease through discovery’, the institute strives to improve health outcomes through discovery, translation and education.

More than 800 bench and clinician scientists in 85 laboratories across 15 research divisions drive innovative programs and develop new approaches for the prevention and treatment of cancer, immunology, autoimmunity and infectious diseases.

The Institute has a strong track record of successful collaborative development projects with both the private and public sectors on an international and national scale.

This strength in translational research can be summarised by the discovery of venetoclax.

Venetoclax was developed based on a landmark discovery by our scientists in 1988. They made the connection between apoptosis and cancer, showing that BCL-2 promotes cancer cell survival (Vaux et al. 1988).

A BH3 mimetic drug activating pro-apoptotic BCL-2 proteins was co-developed for clinical use by AbbVie and Genentech, and clinical trials were held across the globe, including Australia.

The drug was granted breakthrough status in 2015 and FDA approval in 2016 for the treatment of chronic lymphocytic leukemia patients who have the 17p genetic mutation and who have been treated with at least one prior therapy.

This is a remarkable story of collaboration between academia and the pharmaceutical industry that will benefit millions of cancer patients all over the world.

 

SYNthesis Research

SYNthesis Research is a small molecule drug discovery company focussed on both early-stage deal flow and strategic longer-term clinical development programs. Headquartered in Melbourne Australia, SYNthesis Research has established a number of shared risk, drug discovery collaborations with biotech companies and research institutes.

The goal of these shared risk collaborations is to jointly discover and develop novel, small molecule clinical candidates across a range of therapeutic areas. The SYNthesis Research team has a proud history of delivering clinical candidates, and has already built a strong pipeline of maturing drug discovery programs with our partners in the areas of cancer and inflammatory disease.

SYNthesis Research works closely with its sister company SYNthesis Med Chem for access to high quality compound synthesis and medicinal chemistry capabilities and expertise.